×
About 87,103 results

ALLMedicine™ Prostate Cancer Center

Research & Reviews  29,515 results

Oncogenic gene fusions in nonneoplastic precursors as evidence that bacterial infection...
https://doi.org/10.1073/pnas.2018976118
Proceedings of the National Academy of Sciences of the Un... Shrestha E, Coulter JB et. al.

Aug 4th, 2021 - Prostate adenocarcinoma is the second most commonly diagnosed cancer in men worldwide, and the initiating factors are unknown. Oncogenic TMPRSS2:ERG (ERG+) gene fusions are facilitated by DNA breaks and occur in up to 50% of prostate cancers. Infe...

PSMA PET predicts metastasis-free survival in the setting of salvage radiotherapy after...
https://doi.org/10.1016/j.urolonc.2021.06.008
Urologic Oncology; Wenzel M, Hussein R et. al.

Aug 4th, 2021 - To evaluate the impact of PSMA PET (prostate specific membrane antigen positron emission tomography) findings prior to salvage radiotherapy (SRT) in recurrent prostate cancer (PCa) after radical prostatectomy (RP) on metastasis-free survival (MFS)...

Anterior and apical samplings during transperineal image-guided prostate biopsy.
https://doi.org/10.1016/j.urolonc.2021.07.011
Urologic Oncology; Savin Z, Dekalo S et. al.

Aug 4th, 2021 - Concurrent systematic biopsies during image-guided targeted biopsies of the prostate were found to improve the detection rate of clinically significant prostate cancer (CSPC). However, these biopsies do not routinely include anterior or apical sam...

Primary Prostatic Carcinoma With De Novo Diffuse Neuroendocrine Differentiation.
https://doi.org/10.1177/10668969211035844
International Journal of Surgical Pathology; Galea LA, Mow C et. al.

Aug 3rd, 2021 - The 2016 World Health Organization classification of prostate cancer with neuroendocrine (NE) differentiation includes NE cells in usual prostate cancer, adenocarcinoma with Paneth cell-like NE differentiation, well-differentiated NE tumor (carcin...

see more →

Guidelines  63 results

ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but...
https://doi.org/10.1016/j.prro.2020.10.002
Practical Radiation Oncology; Zietman AL,

Dec 15th, 2020 - ASTRO Editorial: The AUA-ASTRO-SUO Advanced Prostate Cancer Guidelines: A Continued but Changing Role for the Radiation Oncologist.|2020|Zietman AL, ,|

Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II.
https://doi.org/10.1097/JU.0000000000001376
The Journal of Urology; Lowrance WT, Breau RH et. al.

Sep 23rd, 2020 - The summary presented herein represents Part II of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with castration-resistant disease. Please refer ...

Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.
https://doi.org/10.1097/JU.0000000000001375
The Journal of Urology; Lowrance WT, Breau RH et. al.

Sep 23rd, 2020 - The summary presented herein represents Part I of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with biochemical recurrence without metastatic di...

American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Relate...
https://doi.org/10.1016/j.prro.2020.06.009
Practical Radiation Oncology; Bauman GS, Jani AB

Sep 7th, 2020 - American Society for Radiation Oncology Editorial: Rapidly Evolving Technologies Related to Imaging Strategies for Advanced Prostate Cancer.|2020|Bauman GS,Jani AB,|

Optimizing the management of castration-resistant prostate cancer patients: A practical...
https://doi.org/10.1002/pros.24053
The Prostate REFERENCES; Shore ND, Drake CG et. al.

Aug 12th, 2020 - Advanced prostate cancer (PC) patients, especially those with metastatic prostate cancer (mPC), often require complex management pathways. Despite the publication of clinical practice guidelines by leading urological and oncological organizations ...

see more →

Drugs  195 results see all →

Clinicaltrials.gov  2,000 results

A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT02407054

May 7th, 2020 - The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY3023414 in combination with enzalutamide in men with prostate cancer.

MR Image Guided Therapy in Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT01377753

May 6th, 2020 - Background: Pilot study is designed to evaluate the safety and feasibility of thermal laser ablation of focal prostate tumors. Prostate cancer is relatively slow growing, with doubling times for local tumors estimated at 2 to 4 years. Some prostat...

Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT02499835

May 6th, 2020 - PRIMARY OBJECTIVES: I. To evaluate the safety of pembrolizumab in combination with pTVG-HP (pTVG-HP plasmid DNA vaccine) in patients with castration-resistant, metastatic prostate cancer. II. To determine the 6-month progression-free survival and ...

Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT02470897

May 5th, 2020 - PRIMARY OBJECTIVES: I. To evaluate the incidence of genitourinary (GU) and gastrointestinal (GI) acute and late toxicity for patients treated with prostate stereotactic body radiotherapy (SBRT) with simultaneous integrative boost, urethral ring sp...

A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
https://clinicaltrials.gov/ct2/show/NCT03706365

May 5th, 2020 - This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednisone...

see more →

News  3,004 results

Common Advanced Prostate Cancer Treatments Not Tied to Significant Cognitive Decline
https://www.medscape.com/viewarticle/955117

Jul 21st, 2021 - (Reuters Health) - Several therapies commonly used to treat men with metastatic castration-resistant prostate cancer don't appear to cause a significant decline in cognitive function, a small study suggests. Researchers examined data on 155 men 65...

Transperineal Prostate Biopsy Safe, Effective Under Local Anesthesia
https://www.medscape.com/viewarticle/954951

Jul 19th, 2021 - NEW YORK (Reuters Health) - Transperineal prostate biopsy with local anesthesia is safe and achieved similar outcomes to sedation in detecting clinically significant cancer in a small retrospective study. "The transperineal approach to prostate bi...

Institute of Cancer Research Criticises NICE Rejection of Abiraterone
https://www.medscape.com/viewarticle/954899

Jul 16th, 2021 - The Institute of Cancer Research (ICR) has expressed disappointment at the decision by The National Institute for Health and Care Excellence (NICE) not to approve abiraterone as a first-line treatment for newly diagnosed, advanced prostate cancer....

MRI Plus New Score Halves Biopsy Rate for Prostate Cancer
https://www.medscape.com/viewarticle/954395

Jul 9th, 2021 - More good tidings to gladden the hearts of men who have reached the half century mark: Swapping traditional prostate biopsies for MRI-targeted biopsies with a new prostate cancer risk score can cut the number of unnecessary biopsies in half while ...

Guideline-Concordant Multimodality Care Tied to Fewer Deaths in High-Risk Prostate Cancer
https://www.medscape.com/viewarticle/954460

Jul 9th, 2021 - NEW YORK (Reuters Health) - In high-risk prostate cancer patients with at least one additional adverse feature, guideline-concordant multimodal care was associated with greater prostate cancer-specific survival (PCSS) in a large retrospective stud...

see more →

Patient Education  64 results see all →